Multiple sclerosis

Best Practice and Research: Clinical Haematology

Volumn 17, Issue 2, 2004, Pages 247-262

  Fassas, Athanasios ^a   Nash, Richard ^b  

^a G PAPANICOLAOU HOSPITAL   (Greece)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Multiple sclerosis; Stem cell transplantation

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; BUSULFAN; CARMUSTINE; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DEXAMETHASONE; ETOPOSIDE; GADOLINIUM; GLATIRAMER; GLUCOCORTICOID; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; MITOXANTRONE; MONOCLONAL ANTIBODY; PREDNISONE; THYMOCYTE ANTIBODY;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DEGENERATIVE DISEASE; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG MEGADOSE; DRUG RESPONSE; HEMOPHILIA; HERPES VIRUS INFECTION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INFLUENZA; LIVER VEIN OBSTRUCTION; LOWER RESPIRATORY TRACT INFECTION; LYMPHOCYTE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MORTALITY; MULTIPLE SCLEROSIS; MYCOSIS; NEUROLOGIC DISEASE; NONHUMAN; PATIENT SELECTION; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; SCORING SYSTEM; STREPTOCOCCUS INFECTION; URINARY TRACT INFECTION; VIRUS INFECTION; AUTOTRANSPLANTATION; CLASSIFICATION; STEM CELL TRANSPLANTATION;

CLINICAL TRIALS; HUMANS; MULTIPLE SCLEROSIS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 4344582789     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2004.04.005     Document Type: Article

References (72)

1. Compston A. Coles A. Multiple sclerosis Lancet 359 2002 1221-1231 Erratum in Lancet 2002; 360: 648
2. Bjartmar C. Wujek J.R. Trapp B.D. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease Journal of the Neurological Sciences 206 2003 165-171
3. Goebels N. Hofstetter H. Schmidt S. et al. Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence Brain 123 2000 508-518
4. Lang H.L.E. Jacobsen H. Ikemizu S. et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis Nature Immunology 3 2002 940-943
5. Wekerle H. Hohlfeld R. Molecular mimicry in multiple sclerosis New England Journal of Medicine 349 2003 185-186
6. Ozenci V. Kouwenhoven M. Huang Y.M. et al. Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-alpha)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment Clinical and Experimental Immunology 120 2000 147-153
7. Kerschensteiner M. Stadelmann C. Dechant G. et al. Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases Annals of Neurology 53 2003 292-304
8. Trapp B.D. Ransohoff R. Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability Current Opinion in Neurology 12 1999 295-302
9. Silber E. Sharief M.K. Axonal degeneration in the pathogenesis of multiple sclerosis Journal of the Neurological Sciences 170 1999 11-18
10. Filippi M. Bozzali M. Rovaris M. et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis Brain 126 2003 433-437
11. Lassmann H. Brain damage when multiple sclerosis is diagnosed clinically Lancet 361 2003 1317-1318
12. Wylezinska M. Cifelli A. Jezzard P. et al. Thalamic neurodegeneration in relapsing-remitting multiple sclerosis Neurology 60 2003 1949-1954
13. Confavreux C. Vukusic S. Moreau T. Adeleine P. Relapses and progression of disability in multiple sclerosis New England Journal of Medicine 343 2000 1430-1438
14. Noseworthy J.H. Lucchinetti C. Rodriguez M. Weinshenker B.G. Multiple Sclerosis New England Journal of Medicine 343 2000 938-952
15. Fredrikson S. Cheng Q. Jiang G.X. Wasserman D. Elevated suicide risk among patients with multiple sclerosis in Sweden Neuroepidemiology 22 2003 146-152
16. Bitsch A. Bruck W. Differentiation of multiple sclerosis subtypes: implications for treatment CNS Drugs 16 2002 405-418
17. Noseworthy J.H. Treatment of multiple sclerosis and related disorders: what's new in the past 2 years? Clinical Neuropharmacology 26 2003 28-37
18. Coles A.J. Wing M.G. Molyneux P. et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis Annals of Neurology 46 1999 296-304
19. Wiendl H. Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials BioDrugs: Immunotherapeutics, Biopharmaceuticals and Gene Therapy 16 2002 183-200
20. Ben-Hur T. Einstein O. Mizrachi-Kol R. et al. Transplanted multipotential neural precursor cells migrate into the inflammed white matter in response to experimental autoimmune encephalomyelitis Glia 41 2003 73-80
21. Pluchino S. Quattrini A. Brambilla E. et al. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis Nature 422 2003 688-694
22. Filippini G. Munari L. Incorvaia B. et al. Interferons in relapsing-remitting multiple sclerosis: a systematic review Lancet 361 2003 545-552
23. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results Neurology 56 2001 1496-1504
24. Kappos L. Polman C. Pozzilli C. et al. Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS Neurology 57 2001 1969-1975
25. Boneschi F.M. Rovaris M. Johnson K.P. et al. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled trials Multiple Sclerosis 9 2003 349-355
26. Gonsette R.E. Mitoxantrone in progressive multiple sclerosis: when and how to treat? Journal of the Neurological Sciences 206 2003 203-208
27. Edan G. Miller D. Clanet M. et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria Journal of Neurology, Neurosurgery, and Psychiatry 62 1997 112-118
28. Hartung H.P. Gonsette R. König N. Mitoxantrone in Multiple Sclerosis Study Group (MIMS) et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, bouble blind, randomised, multicentre trial Lancet 360 2002 2018-2025
29. Weiner H.L. Mackin G.A. Oray E.J. the Northeast Cooperative Multiple Sclerosis Treatment Group et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group Neurology 43 1993 910-918
30. Weiner H.L. Cohen J.A. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects Multiple Sclerosis 8 2002 142-154
31. Ikehara S. Treatment of autoimmune disease by hematopoietic stem cell transplantation Experimental Hematology 29 2001 661-669
32. van Gelder M. van Bekkum D.W. Effective treatment of relapsing experimental autoimmune encephalomyelitis with pseudoautologous bone marrow transplantation Bone Marrow Transplantation 18 1996 1029-1034
33. Karussis D.M. Slavin S. Ben-Nun A. et al. Chronic-relapsing experimental autoimmune encephalomyelitis (CR-EAE): treatment and induction of tolerance, with high dose cyclophosphamide followed by syngeneic bone marrow transplantation Journal of Neuroimmunology 39 1992 201-210
34. Karussis D.M. Slavin S. Lehmann D. et al. Prevention of experimental autoimmune encephalomyelitis and induction of tolerance with acute immunosuppression followed by syngeneic bone marrow transplantation Journal of Immunology 148 1992 1693-1698
35. Karussis D.M. Vourka-Karoussis U. Lehmann D. et al. Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation Journal of Clinical Investigation 92 1993 765-772
36. Karussis D. Vourka-Karussis U. Mizrachi-Koll R. Abramsky O. Acute/relapsing experimantal autoimmune encephalomyelitis: induction of long lasting, antigen-specific tolerance by syngeneic bone marrow transplantation Multiple Sclerosis 5 1999 17-21
37. van Gelder M. Kinwell-Bohre E.P.M. van Bekkum D.W. Treatment of experimental allergic encephalomyelitis in rats with total body irradiation and syngeneic BMT Bone Marrow Transplantation 11 1993 233-241
38. van Gelder M. van Bekkum D.W. Treatment of relapsing experimental autoimmune encephalomyelitis in rats with allogeneic bone marrow transplantation from a resistant strain Bone Marrow Transplantation 16 1995 343-351
39. Burt R.K. Ruvollo P. Hess A. Burns W. Syngeneic bone marrow transplantation in Lewis rats with experimental autoimmune encephalitis Journal of Neuroscience Research 41 1995 526-531
40. Burt R.K. Padilla J. Begolka W.S. et al. Effect of disease stage on clinical outcome after syngeneic bone marrow transplantation for relapsing experimental autoimmune encephalomyelitis Blood 91 1998 2609-2616
41. van Bekkum D.W. New opportunities for the treatment of severe autoimmune diseases: bone marrow transplantation Clinical Immunology and Immunopathology 89 1998 1-10
42. McAllister L.D. Beatty P.G. Rose J. Allogeneic bone marrow transplant for chronic myelogenous leukemia in a patient with multiple sclerosis Bone Marrow Transplantation 19 1997 395-397
43. Meloni G. Salvetti M. Cordone I. et al. Autologous peripheral blood stem cell transplantation in a patient with multiple sclerosis and concomitant Ph+ acute leukemia Haematologica 84 1999 665-667
44. Mandalfino P. Rice G. Smith A. et al. Bone marrow transplantation in multiple sclerosis Journal of Neurology 247 2000 691-695
45. Fassas A. Anagnostopoulos A. Kazis A. et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study Bone Marrow Transplantation 20 1997 631-638
46. Burt R.K. Traynor A.E. Cohen B. et al. T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: report of the first three patients Bone Marrow Transplantation 21 1998 537-541
47. Burt R.K. Traynor A.E. Pope R. et al. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation Blood 92 1998 3505-3514
48. Fassas A. Anagnostopoulos A. Kazis A. et al. Autologous stem cell transplantation in progressive multiple sclerosis - an interim analysis of efficacy Journal of Clinical Immunology 20 2000 24-30
49. Openshaw H. Lund B.T. Kashyap A. et al. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring Biology of Blood and Marrow Transplantation 6 2000 563-575
50. Kozak T. Havrdova E. Pit'ha J. et al. High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis Bone Marrow Transplantation 25 2000 525-531
51. Fassas A. Passweg J.R. Anagnostopoulos A. for the Autoimmune Disease Working Party of the EBMT (European Group for Blood and Marrow Transplantation) et al. Hematopoietic stem cell transplantation for multiple sclerosis: a retrospective multicenter study Journal of Neurology 249 2002 1088-1097
52. Saiz A. Carreras E. Berenguer J. et al. MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS Neurology 56 2001 1084-1089
53. Mancardi G.L. Saccardi R. Filippi M. the Italian GITMO-NEURO Intergroup on Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis et al. Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS Neurology 57 2001 62-68
54. Carreras E. Saiz A. Marin P. et al. CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of the toxicity and treatment results at one year of follow-up in 15 patients Haematologica 88 2003 306-314
55. Nash R.A. Bowen J.D. McSweeney P.A. et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis Blood 102 2003 2364-2372
56. Burt R.K. Cohen B.A. Russel E. et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of intense immune suppression to prevent disease progression in patients with high disability scores Blood 102 2003 2373-2378
57. Fassas A. Anagnostopoulos A. Kazis A. Autologous blood stem cell therapy for progressive multiple sclerosis In Dicke K.A. & Keating A. (Eds.), Autologous Blood and Marrow Transplantation Proceedings of the Ninth International Symposium, Arlington, Texas 1999 452-463 Carden Jennings Charlottesville
58. Saccardi R. Mancardi G.L. Bacigalupo A. et al. Autologous hematopoietic stem cell transplantation in secondary progressive MS: clinical, instrumental findings and impact on quality of life Blood 100 supplement 2002 865a
59. Nash R.A. Dansey R. Storek J. et al. Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases Biology of Blood and Marrow Transplantation 9 2003 583-591
60. Kashyap A. Passweg J. Tyndall A. Autologous hematopoietic stem cell transplant conditioning regimens for the treatment of severe autoimmune diseases In Dicke K.A. & Keating A. (Eds.), Autologous Blood and Marrow Transplantation Proceedings of the Ninth International Symposium, Arlington, Texas 2001 219-225 Carden Jennings Charlottesville
61. Moore J. Brooks P. Milliken S. et al. A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis Arthritis and Rheumatism 46 2002 2301-2309
62. Mezey E. Chandross K.J. Harta G. et al. Turning blood into brain: cells bearing neuronal antigens generated in vivo from bone marrow Science 290 2000 1779-1782
63. Bonilla S. Alarcon P. Villaverde R. et al. Haematopoietic progenitor cells from adult bone marrow differentiate into cells that express oligodendroglial antigens in the neonatal mouse brain European Journal of Neuroscience 15 2002 575-582
64. Mezey E. Key S. Vogelsang G. et al. Transplanted bone marrow generates new neurons in human brains Proceedings of the National Academy of Sciences of the USA 100 2003 1364-1369
65. Kozak T. Havrdova E. Pitha J. et al. Immunoablative therapy with PBPC support with in vitro or in vivo T-cell depletion in patients with poor risk multiple sclerosis Bone Marrow Transplantation 29 supplement 2002 S15
66. Saccardi R. Mancardi G.L. Bacigalupo A. et al. Autologous hematopoietic stem cell transplantation in secondary progressive MS: clinical, instrumental findings and impact on quality of life Blood 100 supplement 2002 865a
67. Kimiskidis V.K. Tsimourtou V. Papagiannopoulos S. et al. Autologous stem cell transplantation in multiple sclerosis: the MRI study Journal of Neurology 249 supplement 2002 I/61
68. Fassas A. Kimiskidis V.K. Stem cell transplantation in multiple sclerosis: what is the evidence? Blood Reviews 17 2003 233-240
69. Openshaw H. Stuve O. Antel J.P. et al. Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor Neurology 54 2000 2147-2150
70. Burt R.K. Fassas A. Snowden J. et al. Collection of hematopoietic stem cells from patients with autoimmune diseases Bone Marrow Transplantation 28 2001 1-12
71. Atkins H.L. Freedman M. Bowman M. et al. Immunoablative therapy with purified autologous stem cells rescue for the treatment of poor prognosis MS Biology of Blood and Marrow Transplantation 9 2003 110
72. Burt R.K. Cohen B.A. Lobeck L. et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: importance of disease stage on outcome Neurology 40 supplement 2003 A150